Discover India's Biopharma Shakti initiative: a ₹10,000-crore plan to enhance biologics, biosimilars, and healthcare standards.
While policy shifts and leadership shakeups at institutions like the Food and Drug Administration dominated headlines in 2025, drugmakers would do well to sift through the noise and remain focused on ...
Industry leaders have said the Union Budget 2026 has laid the groundwork for a major shift in India's pharmaceutical sector, with the Biopharma SHAKTI initiative expected to reduce reliance on ...
Finance Minister Nirmala Sitharaman announces Biopharma Shakti, a ₹10,000 crore plan to boost biologics, biosimilars, clinical trials and regulatory capacity in India.
Budget 2026 | Biopharma SHAKTI: The scheme sits at the intersection of public health imperatives and industrial policy.
Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and ...
Symbolic milestone for new buffer media station: Rentschler Biopharma underscores its commitment to the Laupheim headquarters and to the future of Germany and Europe as leading biotechnology hubs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results